D2c7-It 2024 Results. Annick desjardins, md | trial primary completion date: This dose escalation phase i study is ongoing and will set the stage for the phase ii trial.
Glioblastomas (Gbms) Are Highly Intracranially Invasive And Resistant To Immunotherapy.
The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called d2c7.
This Dose Escalation Phase I Study Is Ongoing And Will Set The Stage For The Phase Ii Trial.
View duration, location, compensation, and staffing details.
Eligible Patients Were Adults With Recurrent.
Images References :
Glioblastomas (Gbms) Are Highly Intracranially Invasive And Resistant To Immunotherapy.
The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called d2c7.
